The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Co-Testing: Pap-Test and mRNA HPV-Test for Cervical Cancer Screening
|
|
Author(s): Maria Halatsi (Diagnostics Department, Aenorasis, Athens, Greece), Evripidis Bilirakis (Hellenic Society of Cervical Pathology and Colposcopy, Greece & IASO Medical Center, Athens, Greece), Stamatios Petousis (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece), Εleftherios Vavoulidis (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece)and Konstantinos Dinas (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece)
Copyright: 2021
Pages: 17
Source title:
Handbook of Research on Oncological and Endoscopical Dilemmas in Modern Gynecological Clinical Practice
Source Author(s)/Editor(s): Konstantinos Dinas (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece), Stamatios Petousis (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece), Matthias Kalder (Department of Obstetrics and Gynaecology, Philipps-University of Marburg, Germany)and George Mavromatidis (2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece)
DOI: 10.4018/978-1-7998-4213-2.ch008
Purchase
|
Abstract
The dramatic decline in cervical cancer in women is attributable first to screening with the Papanicolaou (Pap) test, followed later by the addition of the Human Papilloma Virus (HPV) test, which enhanced screening sensitivity. In association with this excellent performance record, resulting from the combination of Pap Test and HPV Test, known also as Co-Testing, the current standard of care for cervical cancer screening for most women (those over 30) is Co-Testing with Pap + HPV tests, as currently recommended by U.S. guidelines. The challenge is to improve screening cost-effectiveness without compromising efficacy. The notion that screening with one test may be more cost-effective than two tests seems reasonable upon first consideration, but closer examination may dispute this assumption. The chapter aims to analyze costs and benefits regarding optimal screening method for daily clinical practice.
Related Content
|
Genevieve Z. Steiner-Lim, Madilyn Coles, Kayla Jaye, Najwa-Joelle Metri, Ali S. Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan Russo, Tim Karl.
© 2023.
47 pages.
|
|
Mohd Kashif, Mohammad Waseem, Poornima D. Vijendra, Ashok Kumar Pandurangan.
© 2023.
28 pages.
|
|
Courtney R. Acker, Rana R. Zeine.
© 2023.
27 pages.
|
|
Mahesh Pattabhiramaiah, Shanthala Mallikarjunaiah.
© 2023.
16 pages.
|
|
Dhairavi Shah, Dhaara Shah, Yara Mohamed, Danna Rosas, Alyssa Moffitt, Theresa Hearn Haynes, Francis Cortes, Taunjah Bell Neasman, Phani kumar Kathari, Ana Villagran, Rana R. Zeine.
© 2023.
28 pages.
|
|
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar, Shahid Bashir.
© 2023.
23 pages.
|
|
Akila Muthuramalingam, Ashok Kumar Pandurangan, Subhamoy Banerjee.
© 2023.
17 pages.
|
|
|